Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ZURA
stocks logo

ZURA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.188
+135.41%
--
--
-0.190
-0%
--
--
-0.200
+17.65%
Estimates Revision
The market is revising No Change the revenue expectations for Zura Bio Limited (ZURA) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 76.82%.
EPS Estimates for FY2025
Revise Upward
up Image
+3.99%
In Past 3 Month
Stock Price
Go Up
up Image
+76.82%
In Past 3 Month
Wall Street analysts forecast ZURA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZURA is 11.67 USD with a low forecast of 2.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast ZURA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZURA is 11.67 USD with a low forecast of 2.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 3.890
sliders
Low
2.00
Averages
11.67
High
18.00
Current: 3.890
sliders
Low
2.00
Averages
11.67
High
18.00
Clear Street
NULL
to
Buy
initiated
$18
2025-11-12
Reason
Clear Street
Price Target
$18
2025-11-12
initiated
NULL
to
Buy
Reason
Clear Street initiated coverage of Zura Bio with a Buy rating and $18 price target. The firm said he rating reflects "strong conviction" in tibulizumab's ability to lead in hidradenitis suppurativa and systemic sclerosis. The firm also believes tibulizumab is well positioned to set a new standard.
H.C. Wainwright
H.C. Wainwright
Neutral
downgrade
$3 -> $2
2025-08-19
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$3 -> $2
2025-08-19
downgrade
Neutral
Reason
H.C. Wainwright lowered the firm's price target on Zura Bio to $2 from $3 and keeps a Neutral rating on the shares. The firm updated the company's model post the Q2 report to reflect increases in potentially dilutive shares outstanding.
Oppenheimer
Oppenheimer
Outperform
downgrade
$17 -> $16
2025-08-15
Reason
Oppenheimer
Oppenheimer
Price Target
$17 -> $16
2025-08-15
downgrade
Outperform
Reason
Oppenheimer lowered the firm's price target on Zura Bio to $16 from $17 and keeps an Outperform rating on the shares after the company reported Q2 financial results and provided an update on their ongoing clinical studies of tibulizumab, with the global Phase 2 TibuSHIELD study in HS having launched in May. The firm's reported Q2 ending cash of $154.5M is anticipated to support operations through 2027 and readouts from both ongoing studies of tibulizumab.
Oppenheimer
Oppenheimer
Outperform
downgrade
$19 -> $17
2025-05-09
Reason
Oppenheimer
Oppenheimer
Price Target
$19 -> $17
2025-05-09
downgrade
Outperform
Reason
Oppenheimer lowered the firm's price target on Zura Bio to $17 from $19 and keeps an Outperform rating on the shares. The firm notes Zura reported Q1 results with tibulizumab continuing to advance. The Phase 2 TibuSURE trial in SSC is active with efforts focused on site contracting and activation. Next up the HS study is slated to begin Q2 2025.
HC Wainwright & Co.
Mitchell Kapoor
Hold
Maintains
$5 → $3
2025-04-03
Reason
HC Wainwright & Co.
Mitchell Kapoor
Price Target
$5 → $3
2025-04-03
Maintains
Hold
Reason
Chardan Capital
Matthew Barcus
Strong Buy
Maintains
$12 → $10
2025-03-26
Reason
Chardan Capital
Matthew Barcus
Price Target
$12 → $10
2025-03-26
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Zura Bio Ltd (ZURA.O) is -5.02, compared to its 5-year average forward P/E of -4.59. For a more detailed relative valuation and DCF analysis to assess Zura Bio Ltd 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.59
Current PE
-5.02
Overvalued PE
-1.81
Undervalued PE
-7.38

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

ZURA News & Events

Events Timeline

(ET)
2025-11-13
06:36:34
Zura Bio Announces Q3 Earnings Per Share of 21 Cents, Exceeding Consensus Estimate of 18 Cents
select
2025-08-11 (ET)
2025-08-11
09:44:06
Novartis trial has positive read for Zura Bio, says Guggenheim
select
2025-07-01 (ET)
2025-07-01
06:31:55
Zura Bio appoints Eric Hyllengren as CFO
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
6.0
11-15Benzinga
Chardan Capital Reaffirms Buy Rating on Zura Bio with $10 Price Target Intact

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.

  • Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and experiences.

  • Market Winning Tools: The platform provides essential tools and information that traders use daily to succeed in the markets.

[object Object]
Preview
9.5
11-13Newsfilter
Zura Bio Announces Financial Results for Q3 2025 and Latest Corporate Developments

  • Clinical Trials Update: Zura Bio is advancing two Phase 2 clinical trials for tibulizumab, targeting hidradenitis suppurativa and systemic sclerosis, with topline data expected in 2026.

  • Financial Position: As of September 30, 2025, Zura Bio reported $139 million in cash, sufficient to fund operations through 2027, despite a net loss of $20 million for the third quarter.

  • Research and Development Expenses: R&D expenses increased to $11.9 million in Q3 2025, reflecting ongoing clinical trial advancements, while general and administrative expenses decreased to $7.6 million.

  • Company Overview: Zura Bio focuses on developing dual-pathway antibodies for autoimmune diseases, with tibulizumab as its lead candidate currently in clinical trials.

[object Object]
Preview
9.0
10-24NASDAQ.COM
INBX Rises 81% Following Study Results; FEMY, CING, CYH Surge in After-Hours Trading

  • Inhibrx Biosciences Surge: Inhibrx Biosciences (INBX) shares soared over 81% after positive Phase 2 trial results for ozekibart in treating advanced chondrosarcoma, alongside updates on other cancer treatment studies.

  • Femasys Gains: Femasys Inc. (FEMY) saw an 18% increase following the launch of a post-market clinical study for its FemBloc Permanent Birth Control, complying with EU regulations.

  • Cingulate's Presentation: Cingulate Inc. (CING) rose over 6% after announcing that data from its ADHD treatment candidate, CTx-1301, will be presented at the AACAP Annual Meeting, highlighting its potential in ADHD management.

  • Community Health Systems Performance: Community Health Systems, Inc. (CYH) shares increased over 4% after reporting positive Q3 results, contributing to a generally favorable after-hours trading environment for biotech stocks.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Zura Bio Ltd (ZURA) stock price today?

The current price of ZURA is 3.89 USD — it has increased 5.71 % in the last trading day.

arrow icon

What is Zura Bio Ltd (ZURA)'s business?

Zura Bio Limited is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies. It is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other indications with unmet needs. ZB-106 is an immunoglobulin G single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of TALTZ and tabalumab that neutralize interleukin-17A (IL-17A) and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain alpha chain. ZB-880 is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation.

arrow icon

What is the price predicton of ZURA Stock?

Wall Street analysts forecast ZURA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZURA is 11.67 USD with a low forecast of 2.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Zura Bio Ltd (ZURA)'s revenue for the last quarter?

Zura Bio Ltd revenue for the last quarter amounts to -19.52M USD, increased 1.04 % YoY.

arrow icon

What is Zura Bio Ltd (ZURA)'s earnings per share (EPS) for the last quarter?

Zura Bio Ltd. EPS for the last quarter amounts to -15476000.00 USD, increased 173.14 % YoY.

arrow icon

What changes have occurred in the market's expectations for Zura Bio Ltd (ZURA)'s fundamentals?

The market is revising No Change the revenue expectations for Zura Bio Limited (ZURA) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 76.82%.
arrow icon

How many employees does Zura Bio Ltd (ZURA). have?

Zura Bio Ltd (ZURA) has 30 emplpoyees as of December 05 2025.

arrow icon

What is Zura Bio Ltd (ZURA) market cap?

Today ZURA has the market capitalization of 251.64M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free